NDA 218033 · Day One Biopharms
Ojemda
Tovorafenib · Oral · Kinase Inhibitor
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Apr 23, 2024: To treat relapsed or refractory pediatric low-grade glioma
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 23, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
1 Phase 3, 5 recruiting
FAERS reports
326
108 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 2, 2025.
OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. ( 1 ) This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: Tovorafenib is a Type II RAF kinase inhibitor of mutant BRAF V600E , wild-type BRAF , and wild-type CRAF kinases. Tovorafenib exhibited antitumor activity in cultured cells and xenograft tumor models harboring BRAF V600E and V600D mutations, and in a xenograft model harboring a BRAF fusion.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2025 Supplement 2 · Efficacy OrphanLabelLetter
- Apr 23, 2024 Original approval · Type 3 - New Dosage Form · priority review NovelAccelerated approvalOrphanLetterLabelReview
1 products under this application
- OJEMDA · TOVORAFENIB 25MG/ML · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tovorafenib" as an intervention, any sponsor and status, largest first.
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Pivotal-lookingActive, not recruiting
Day One Biopharmaceuticals, Inc.Industry
NCT05566795 · 418 participants · Start Feb 27, 2023 · Primary completion Jun 2027
Drug: Tovorafenib; Chemotherapeutic Agent · For: Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 138 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01425008 · 149 participants · Start Sep 15, 2011 · Primary completion Apr 11, 2017
Drug: MLN2480 · For: Melanoma; Metastatic Melanoma; Solid Tumor and 1 more
Sites: San Francisco, California; Denver, Colorado; Augusta, Georgia · 16 sites in all
Day One Biopharmaceuticals, Inc.Industry
NCT04775485 · 141 participants (planned) · Start Apr 22, 2021 · Primary completion May 31, 2027
Drug: Tovorafenib · For: Low-grade Glioma; Advanced Solid Tumor
Sites: San Francisco, California; Washington D.C., District of Columbia; Chicago, Illinois · 35 sites in all
National Cancer Institute (NCI)NIH
NCT06965114 · 84 participants (planned) · Start May 29, 2026 · Primary completion Mar 1, 2030
Drug: Cladribine; Rituximab and 1 more · For: Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia; Refractory Hairy Cell Leukemia
Sites: Bethesda, Maryland; Columbus, Ohio; Pittsburgh, Pennsylvania · 4 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02327169 · 81 participants · Start Jan 14, 2015 · Primary completion Jul 2, 2018
Drug: MLN2480; MLN0128 and 4 more · For: Advanced Nonhematologic Malignancies
Sites: Boston, Massachusetts; Philadelphia, Pennsylvania; Houston, Texas · 14 sites in all
- Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Not yet recruiting
Nationwide Children's HospitalAcademic, hospital or other
NCT07206849 · 79 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: Tovorafenib · For: High Grade Glioma (HGG) of the Brain With BRAF Aberration; High Grade Glioma (III or IV); Diffuse Intrinsic Pontine Glioma and 4 more
Daniel MorgensternAcademic, hospital or other
NCT06381570 · 57 participants (planned) · Start Mar 21, 2024 · Primary completion Mar 21, 2027
Drug: Tovorafenib; Vinblastine · For: Low-grade Glioma
Sites: Toronto, Canada
Sabine Mueller, MD, PhDAcademic, hospital or other
NCT05465174 · 57 participants (planned) · Start Sep 12, 2022 · Primary completion Mar 1, 2027
Drug: Tovorafenib · For: Craniopharyngioma, Child; Craniopharyngioma; Recurrent Craniopharyngioma
Sites: Birmingham, Alabama; San Diego, California; San Francisco, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use34
- disease progression28
- rash27
- fatigue23
- accidental underdose19
- hair colour changes18
- headache17
- melanocytic naevus15
- growth retardation12
- blood creatine phosphokinase increased11
- nausea11
- acne10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 69 |
| 2025 | 179 |
| 2026 | 78 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ojemda (Tovorafenib)
2024 spending
$705K
Beneficiaries
n/a
21 claims
Per beneficiary
n/a
$1,466.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $704,813 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB, Khuong-Quang DA, Hansford JR, et al. · Nat Med 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.
Singh S, Bradford D, Chatterjee S, et al. · Clin Cancer Res 2025 · Clinical Trial, Phase II, Multicenter Study
- LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM, Kilburn LB, Perreault S, et al. · BMC Cancer 2024 · Randomized Controlled Trial, Multicenter Study
- Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco DW, Medina T, Corrie P, et al. · Cancer Chemother Pharmacol 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
Vieito M, Cabanas EG, Mehmi I, et al. · JCO Precis Oncol 2026 · Clinical Trial, Phase II, Multicenter Study
- Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
Nysom K, Kilburn LB, Leary SES, et al. · Neuro Oncol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Day One Biopharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.